Related Experiment Videos
[Acute infections in pediatric surgery. Clinical experience with clindamycin (author's transl)]
Insights
Clindamycin effectively treated pediatric infections in 83% of cases, primarily targeting Gram-positive bacteria like Staphylococci and Streptococci. Poor outcomes were linked to Gram-negative infections.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Therapy
Background:
- Postsurgical wound infections, sepsis, and other serious conditions are common in children.
- Gram-positive bacteria, particularly Staphylococci and Streptococci, are frequent causative agents.
- Effective antibiotic treatment is crucial for favorable patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of clindamycin in treating various pediatric infections.
- To determine the spectrum of infectious agents involved in these pediatric cases.
- To identify factors associated with treatment success or failure.
Main Methods:
- A retrospective analysis of 76 children treated with clindamycin (40 mg/kg/day).
- Infections included postsurgical wound infections, sepsis, phlegmon, peritonitis, osteomyelitis, pneumonia, mediastinitis, pyoderma, and urinary tract infections.
- Identification of causative microorganisms and assessment of treatment outcomes.
Main Results:
- Clindamycin therapy was successful in 83% of the pediatric patients.
- Predominant infectious agents were Staphylococci (94.7%) and Streptococci (59.2%).
- Treatment failure occurred in cases with predominantly Gram-negative organisms, including Escherichia coli and Pseudomonas.
Conclusions:
- Clindamycin demonstrates significant efficacy in treating a range of pediatric infections, especially those caused by Gram-positive bacteria.
- The drug's effectiveness may be limited in infections with a significant Gram-negative bacterial component.
- Further investigation into clindamycin's role against specific Gram-negative pathogens is warranted.
Abstract:
76 children were treated with clindamycin at a dosage of 40 mg/kg/day for postsurgical wound infections, sepsis, phlegmon, peritonitis, osteomyelitis, pneumonia, mediastinitis, pyoderma and urinary tract infections. Frequency distribution of individual infectious agents: Staphylococci, 94,7%; Streptococci, 59,2%; Pneumococci, 5,3%; Enteroccocci, 25%; Escherichia coli, 10,5%; Pseudomonas, 14,5%; Proteus, 7,9%; Bacteroides, 6,6%; Clostridia, 7,9%. Therapy was successful in 83% of cases. Results were poor in 2 children treated for phlegmona, one case of mediastinitis and one of urinary tract infection, since organisms were predominantly gram-negative.